Toxicity and quality of life outcomes in ovarian cancer patients participating in randomized controlled trials
✍ Scribed by Elfriede R. Greimel; Vesna Bjelic-Radisic; Jacobus Pfisterer; Felix Hilpert; Fedor Daghofer; Eric Pujade-Lauraine; Andreas du Bois; for the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR) and the Groupe d’Investigateurs Nationaux pour les Etudes des Cancers de l’Ovaire (GINECO)
- Publisher
- Springer-Verlag
- Year
- 2010
- Tongue
- English
- Weight
- 168 KB
- Volume
- 19
- Category
- Article
- ISSN
- 0941-4355
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
## Abstract ## BACKGROUND Health related quality of life (HRQOL) is increasingly reported as an important endpoint in cancer clinical trials. However, evidence suggests that HRQOL reporting is often inadequate. Given this, the authors undertook a systematic review to evaluate HRQOL assessment meth